Michel Vounatsos, Biogen CEO (Credit: World Economic Forum/Valeriano Di Domenico)
Biogen slashes Aduhelm price in half, foreshadows significant layoffs as sales continue to stagnate
In a surprise move, Biogen announced Monday that it will cut the price of its controversial Alzheimer’s drug Aduhelm in half, slashing the cost from …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
